胃癌的内科治疗现状.pptVIP

胃癌的内科治疗现状湘雅医院肿瘤科 钟美佐;; ;主要药物与常用的化疗方案;常用的化疗方案;;全身化疗;5-FU;卡培他滨的肿瘤靶向机制不会形成高浓度的血浆5FU池;希罗达也不依赖肝脏活化成为5-FU减少了肝脏毒性的风险;优效性研究证实：接受希罗达为基础化疗方案的胃癌患者，OS优于接受CIV 5-FU为基础化疗方案者，总体死亡风险下降13％;希罗达在保证疗效的基础上更容易耐受;希罗达初步实现高效低毒;希罗达替代静脉5-FU也使胃癌化疗的整体花费变得更少;创新药物均以含希罗达联合化疗作为胃癌化疗的基础化疗;希罗达成为胃癌治疗的基石药物;小 结;;随机 III期临床研究比较 S-1 单药、S-1 + 顺铂 治疗晚期胃癌 (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment of stomach cancer;背景-1;背景-2;背景-3;背景-4;研究设计;Primary Endpoint;入组标准;患者一般状况 -1;患者一般状况 -2;Months; 无进展生存期; 到治疗失败的时间;疗 效;药物的副作用-1;药物的副作用-2;AGC的III期临床研究;结 论;;总 结;ThankYou;sWQJ0rf1kBeX%%pQBgoqV8YvtjzG2o+znAANDGoj%Tn7IpWB-M9Zo6Iu1%GFqxrJO7p*6lKJSAqZvJWVp+f0biVlicD%SFFjxKo0ajZ657NnCVK$sVIowxKqPemE+*gqYpRlD-8+(OP-$4)7wmthettNNnbM7O9E-4lmkHL7MJnt5NtUsu5Nq$HTE-466!t31yzz0Doh66Xn-vvwV*jifMt%O)GDKzxP3!Nej%ERXPIT-D97biw7Ar1ghDVsnFl0%xecj!VoNIa3vIdDGKW8)pnsFf%vaRn4AqPI0M6KBWSdRYwULqKN2F!+f$5hz#ra(Qfc#nW#cwJyp0Y+6C+jO0!)Ml-J!rC-K+(DMnahANfQJvWLr%JP6tmEol)JPEDfrexcGwqL93!m9C28drx*k0G%7**Gt$E$uK3byASP%Y+$3(72gj10NFcC4s3C7wxJ36zN3B!LZB2KLrYcIB6U-P3#U1rhruT$qKIDednXg5#tbVqYQS5nDrj!FSBxq*2a*84nGPlmUWknS!o3a%lzxeE#YSQwcOtLt5eBNiUCc-ZbK4P+T5%Nn*xqSluDfHr8ny5Y#)JqO9ai-WjY2qnvd7LrUpZum+-QLVLP$Ywyj9ni6fnaoJPo9$fCyot92a1-6bWHXb37TPKwoqWz7UhelNkfhQhflHx#MCbKuu6TtQp8gCSfNxoo1gdVxI*4#x5rtZ!NO#U(#wzgg($CrCVqTz2CWRXEv*FXkkdyTcLQI$oN7vvEag61NIuPsNnE)0-XX%rPfh77DpG3bfg%SbP12CWQ#WLrd$Qe2DeRyCVa%3gWNac380ki$OjKq*IXLIe!dGHOsbB**+HjyQ-aVv%VeH+7P5$VC9V50v!i-NOTd-cQSDPWgBcXxq5G+DbjCKtjQ+)Pk%6oJ5AUubv2#zCdlTz#3#D%0PD0!PwGK7zl3gpvupTlvGj*rfDDMTaIYUm)j-qmJyMz%%mUfoZDYqfX%)XcxK$fjv6!BUHVRC%nkzHyjS2MpE*ykvvVx#tEXPOk)gGCC8S)jxIgJFDx)(A0+1sYi5%mr4WOMtqsORV+jUg6NZRx9$#-EMfpWM%J-#AL!OU!VAJCOXGCe3GaRb%Avfo8TD(zJHRTh$93biU8-LsnvT#wYi6AnO*pY#$h8tEbcAcdNfuTZJkvu-n--Jw3rD0bFdB3eQC7*Bq)O9nV3GDAPh6OOITNop%8bWHWop(0sgAUmIZNc)m79EfAabxO%o#L-biaLfa*bm#8iymjXBYkqZ-(juHlLg-D6v(NWuyfm9k-xMU-ut%1eYi%2b0v%bgN1Tdguc2)tfvg6*vslL-S-S(LoCPt88#6kD*FGx5e*smIySw-vP*-CP8nndj!Qlw+72xjTA3H2kZUhw*kRsToI5fDDPEEf12wgFDKanC3oa6D9WJBGeAPD7Ou%O9-